To Document the Burden of Illness on the Quality of Life and the Impact on Healthcare Utilization in (Beta) β-thalassemia Subjects Who Are Transfusion Dependent (TD) and Non-transfusion Dependent (NTD) Receiving Standard of Care
- Conditions
- Interventions
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 100
- Registration Number
- NCT02626689
- Locations
- 🇬🇷
Aghia Sofia Children's Hosptial, Athens, Goudi, Greece
🇮🇹Fondazione IRCCS Ca Granda Ospedale Maggiore, Milano, Italy
🇱🇧American University of Beirut Medical Center, Beirut, Lebanon
Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 12
- Registration Number
- NCT02620800
- Locations
- 🇺🇸
Tufts - New England Medical Center, Boston, Massachusetts, United States
🇺🇸Gibbs Cancer Center and Research Institute, Spartanburg, South Carolina, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 114
- Registration Number
- NCT02616640
- Locations
- 🇺🇸
Local Institution - 108, Boston, Massachusetts, United States
🇺🇸Local Institution - 115, Boston, Massachusetts, United States
🇪🇸Local Institution - 504, Madrid, Spain
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
- Conditions
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 336
- Registration Number
- NCT02604433
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇦🇺Royal Adelaide Hospital Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
🇬🇷Laiko General Hospital of Athens, Ampelokipi - Athens, Greece
An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 41
- Registration Number
- NCT02601300
- Locations
- 🇧🇬
Multiprofile Hospotal for Active Treatment- Sveti Nikolay Chudotvoretz - LOM EOOD, Lom, Bulgaria
🇸🇰Fakultna nemocnica s poliklinikou F. D. Roosevelta, Banska Bystrica, Slovakia
🇧🇬Multiprofile Hospital for Active Treatment Doverie AD, Sofia, Bulgaria
Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 701
- Registration Number
- NCT02596893
- Locations
- 🇺🇸
Texas Digestive Disease Consultants - Dallas, Arlington, Texas, United States
🇺🇸ClinSearch LLC, Chattanooga, Tennessee, United States
🇨🇦CHUS Hopital Fleurimont, Sherbrooke, Quebec, Canada
An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 319
- Registration Number
- NCT02577406
- Locations
- 🇨🇦
Local Institution - 201, Toronto, Ontario, Canada
🇦🇺Local Institution - 904, Adelaide, South Australia, Australia
🇺🇸Local Institution - 111, Chicago, Illinois, United States
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 2494
- Registration Number
- NCT02576717
- Locations
- 🇺🇸
Local Institution - 110, Berkeley, California, United States
🇺🇸Local Institution - 123, Port Charlotte, Florida, United States
🇺🇸Local Institution - 179, Round Rock, Texas, United States
Treatment of Pancreatic Cancer With Abraxane
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 317
- Registration Number
- NCT02555813
- Locations
- 🇦🇹
LKH Feldkirch, Feldkirch, Austria
🇦🇹KH Krems, Krems, Austria
🇦🇹LKH Leoben, Leoben, Austria
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 150
- Registration Number
- NCT02555839
- Locations
- 🇦🇹
AKH, Universitätsklinik für Innere Medizin I /Klin. Abteilung für Onkologie, Vienna, Austria
🇦🇹LKH Feldkirch, Intern E, Hämatologie, Feldkirch, Austria
🇦🇹SCRI-CCCIT gemeinnützige GmbH & Universitätsklinikum der PMU Salzburg Gemeinnützige Salzburger Landeskliniken BetriebsgmbH, Salzburg, Austria